RepliFate · DNA replication at the heart of cell fate decisions and cancer development
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2022-10-01 → 2026-09-30
- EU contribution
- €2,650,313
- Participants
- 21
- Scheme
- HORIZON-TMA-MSCA-DN
Lines connect the coordinator with its partners.
Results in brief
DNA replication at the heart of cell fate decisions and cancer development
RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity. RepliFate investigates the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent the development of cancer. We shift the paradigm in the field to place DNA replication at the center stage as the driver of cell identity and not a mere bystander. This approach paves the way for the development of innovative treatments by exploring the links between DNA replication and cell fate, the immune response and cancer. Thus, RepliFate contributes to the promotion of health and well-being in the European society. In particular we tackle Mission Cancer set on the Horizon Europe by contributing to the objectives Understand and Optimise in Mission Cancer. RepliFate is a meeting point of academia, industry and society to promote research in the field of DNA replication in health and disease. RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. We have created an outstanding training program to foster independent and out-of-the-box views in the fellows to train them as the future leaders in the field. RepliFate bridges basic and applied science to improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.
Data: CORDIS, © European Union
Project objective
RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity. RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation.RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.
Original text from CORDIS.
Participants
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS · MadridCoordinatorSpain
- ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
- ADELIS · LabegeFrance
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisFrance
- EFIIS SISTEMIKI VIOLOGIA MONOPROSOPI IKE · PATRAGreece
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamNetherlands
- FUNDACION CIENTIFICA DE LA ASOCIACIÓN ESPANOLA CONTRA EL CANCER · MadridSpain
- FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III · MadridSpain
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH · NeuherbergGermany
- KOBENHAVNS UNIVERSITET · KOBENHAVNDenmark
- LEAD DISCOVERY CENTER GMBH · DortmundGermany
- PANEPISTIMIO PATRON · RIO PATRASGreece
- PRISMA ASOCIACION PARA LA DIVERSIDAD AFECTIVO-SEXUAL Y DE GENERO EN CIENCIA TECNOLOGIA E INNOVACION · PAMPLONASpain
- SCIENSEED SL · MADRIDSpain
- STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS · AmsterdamNetherlands
- UBIQ BIO BV · AmsterdamNetherlands
- UNIVERSIDAD AUTONOMA DE MADRID · MadridSpain
- UNIVERSIDAD DE SEVILLA · SevillaSpain
- UNIVERSIDAD INTERNACIONAL DE ANDALUCIA · SEVILLASpain
- UNIVERSITAT ZURICH · ZurichSwitzerland
- UNIVERSITE DE MONTPELLIER · MontpellierFrance
Links
- View on CORDIS
- DOI: 10.3030/101072903
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5071aa48f&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50cba7afe&appId=PPGMS
Data: CORDIS, © European Union